Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 35015069.
- Also identified by DOI 10.1001/jamanetworkopen.2021.42703 and PMC identifier 8753497.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study evaluates changes in the rate of germline BRCA testing among patients with ovarian cancer between 2008 and 2018 and analyzes factors associated with testing rates.
Medical subject headings
- Genetic Testing
- Insurance, Health
- Ovarian Neoplasms